Merus (MRUS) delivered a "flawless victory" in its interim data of the mid-stage study of petosemtamab plus pembrolizumab in head and neck squamous cell carcinoma, Truist Securities said in a Thursday note.
The study's results showing a 79% overall survival rate at 12-month was "unquestionably stronger" than competing treatment of ficerafusp alfa with pembrolizumab, Truist analysts said.
"These data reinforce our view that Peto is best-in-class," they said. "We are encouraged by MRUS indicating that data from one or both Phase 3 programs could be reported in 2026."
Truist reiterated its buy rating with a price target of $88.
Price: 54.26, Change: +12.66, Percent Change: +30.43
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。